Status:
UNKNOWN
Evaluation of the Effectiveness and Safety of ABAStroke
Lead Sponsor:
ABAStroke Sp. z o.o.
Conditions:
Stroke
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The aim of the project is to confirm the effectiveness and safety of the ABAStroke technology, which uses the principles of Applied Behavior Analysis (ABA) in the rehabilitation of cognitive deficits ...
Eligibility Criteria
Inclusion
- Men and/or women between the ages of 18 and 70
- Condition after an ischemic or hemorrhagic stroke that occurred within the last 6 months before the start of the study.
- MoCA score \>14 and \<26 points.
- Signing of the informed consent form by each study participant.
Exclusion
- Vision disorders of various etiologies, which, in the opinion of the researcher, prevent the efficient use of a device using electronic displays.
- Psychotic episodes and/or manic episodes and/or severe depression (Beck score 26 or higher) in the past year.
- History of alcohol abuse or physical dependence on opioids in the past 2 years.
- Unwillingness or inability to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social circumstances) that could affect the patient's ability to attend scheduled appointments and use the investigational technology as determined by the investigator.
- MoCA score \<15 or \>25 points.
- Treatment of procognitive drug therapy in the last 6 months before inclusion in the study:
- nootropics (pro-cognitive): cerebrolysin, citicoline, vinpocetine, nicergoline, piracetam, Gingo Biloba preparations, lecithin, cholinesterase inhibitors: donepezil, rivastigmine, galantamine, NMDA receptor antagonist: memantine.
Key Trial Info
Start Date :
July 13 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05979324
Start Date
July 13 2023
End Date
May 31 2024
Last Update
August 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Department of Neurology of the Jagiellonian University Hospital
Krakow, Poland